drugset / Trial / NCT05410860

Efficacy and Safety Study of Etripamil Nasal Spray Self-Administration for the Termination of Spontaneous Episodes of Paroxysmal Supraventricular Tachycardia

NCT05410860 ↗

RandomizedParallel-groupTriple-blindTreatment

Summary

To determine whether etripamil nasal spray (NS) self-administered by Chinese patients is superior to placebo at terminating episodes of PSVT in an at-home setting; To evaluate the efficacy of etripamil NS self-administered by Chinese patients compared with placebo on a range of clinical markers. To evaluate the safety of etripamil NS self-administered by Chinese patients compared with placebo

Timeline

Start
2022-06-30
Primary completion
2024-08-02
Completion
2024-12-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Etripamil Small molecule 70 mg Intranasal